Sign in
Taking people in United StatesPhase 3

Long-term ritlecitinib study for children with severe alopecia areata

Tests ritlecitinib capsules over time in children with severe alopecia areata.

Key facts

Who runs it
Pfizer
Where
Albuquerque, Aurora, Austin, Charleston, Corpus Christi, El Paso, Hershey, Indianapolis, Irvine, Marriottsville, Miami, Milwaukee, Omaha, Pflugerville, Portland, San Antonio, Santa Ana, Skokie, Washington D.C., and Waterford, United StatesSee the 23 sitesAlso in 8 other countries, 51 sites
Registry title
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
Status
Recruiting
Phase
Phase 3
People taking part
140 people, planned
Started
10 Sept 2025
Expected to end
26 Jun 2030
Type of study
Interventional, 2 groups
Treatments tested
  • Ritlecitinib higher dose
  • Ritlecitinib lower dose
Record updated
15 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children with severe alopecia areata, a condition that causes hair loss, who completed study B7981027 or B7981031. All will take ritlecitinib for up to 3 years.

Age
6 Years to 14 Years
Sex
All sexes
Disease stage
Alopecia areata, including alopecia totalis (AT) and alopecia universalis (AU). Children from study B7981031 need at least 50% scalp hair loss (SALT score of ≥50) at Screening and Baseline.
Earlier treatment
Must have completed study B7981027 or B7981031. The summary says children must have had 2 doses of varicella (chickenpox) vaccine, or a past varicella zoster infection shown by blood test.

Main reasons for not taking part

  • Safety events in the earlier study, or since then, that would require stopping treatment for good under this study's rules
  • Leaving the earlier study for a non-safety reason, unless that reason has been resolved
  • Cancer now or in the past, or lymphoproliferative disorders (abnormal growth of immune cells)
  • Active or latent tuberculosis (TB) that is untreated or not treated enough
  • Past severe CMV, shingles or widespread herpes simplex infection, or hepatitis B or hepatitis C infection

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants with alopecia areata (AA) (including alopecia totalis [AT] and alopecia universalis [AU]) who completed the studies B7981027 or B7981031
  • For participants originating from Study B7981031: At least 50% scalp hair loss due to AA (ie, a SALT score of ≥50) at both the Screening and Baseline visits

Who cannot take part

  • Exclusion criteria for participants originating from Study B7981027 with ≤ 30 Days between last dose in Study B7981027 and first visit of Study B7981028; During Study B7981027 or in the period between the last dose of study intervention in Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol; Study participants discontinued from Study B7981027 due to issues other than safety-related events and considered by the investigator for enrolment in Study B7981028 must have resolution of the issue(s) resulting in discontinuation from the parent study prior to enrolment in Study B7981028
  • Exclusion criteria for participants originating from Study B7981031 or from Study B7981027 with >30 Days between last dose in Study B7981027 and first visit of Study B7981028; During Study B7981031 or Study B7981027 or in the period between the last dose of study intervention in Study B7981031 or Study B7981027 and the first dose of study intervention of Study B7981028, presence of safety events that would require permanent discontinuation based on the B7981028 protocol; Any present malignancies or history of malignancies or lymphoproliferative disorders; Evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection, history (one or more episodes) of severe or serious cytomegalovirus (CMV), herpes zoster (shingles) or disseminated herpes simplex, infection with hepatitis B virus (HBV) or hepatitis C virus (HCV); -

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 14 years old?

Where in United States

Also in 8 other countries, 51 sites

  • University of New Mexico Health Sciences CenterAlbuquerque, United StatesTaking people
  • University of New Mexico-IDS PharmacyAlbuquerque, United StatesTaking people
  • Children's Hospital ColoradoAurora, United StatesTaking people
  • Dell Children's Medical CenterAustin, United StatesNot yet recruiting
  • Medical University of South Carolina - South Carolina Translational Research Nexus ClinicCharleston, United StatesTaking people
  • Driscoll Children's HospitalCorpus Christi, United StatesTaking people
  • 3A ResearchEl Paso, United StatesTaking people
  • Penn State Health Milton S. Hershey Medical CenterHershey, United StatesTaking people
  • Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesTaking people
  • University of California, IrvineIrvine, United StatesTaking people
  • Kindred Hair and Skin CenterMarriottsville, United StatesNot yet recruiting
  • Pediatric Skin ResearchMiami, United StatesTaking people
  • Children's WisconsinMilwaukee, United StatesNot yet recruiting
  • Medical College of WisconsinMilwaukee, United StatesNot yet recruiting
  • Ear, Nose & Throat Consultants, LLCOmaha, United StatesTaking people
  • Skin Specialists, PC dba Schlessinger MDOmaha, United StatesTaking people
  • Austin Institute for Clinical ResearchPflugerville, United StatesTaking people
  • Northwest Dermatology InstitutePortland, United StatesTaking people
  • Texas Dermatology and Laser SpecialistsSan Antonio, United StatesTaking people
  • Southern California Clinical ResearchSanta Ana, United StatesTaking people
  • Endeavor Health Clinical OperationsSkokie, United StatesTaking people
  • Children's National HospitalWashington D.C., United StatesTaking people
  • Michigan Dermatology InstituteWaterford, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this clinical trial is to learn about long-term safety and long-term effects of the study medicine (called ritlecitinib) for the potential treatment of severe alopecia areata, a condition that causes hair loss.

Read full original descriptionShow less

This study is seeking participants who have:

* previously completed one of Pfizer's pediatric studies for Alopecia Areata (B7981027 or B7981031). * at least 50% scalp hair loss due to alopecia areata (for participants enrolling from the study B7981031). * received varicella vaccination (2 doses) or have been infected by varicella zoster virus before based on blood test reports.

All participants in this study will receive the study medicine (ritlecitinib). Participants who received ritlecitinib higher or lower doses in the parent Study B7981027 will continue receiving the same ritlecitinib dose in this trial.

Participants who received placebo in the parent Study B7981027 and all participants from parent Study B7981031 will receive either higher or lower dose of ritlecitinib in this trial.

The study medicine is a capsule that is taken by mouth. It is taken 1 time each day at home.

The study will help see if ritlecitinib is safe and effective. Participants will take part in this study for a duration of up to 3 years (36 months). During this time, they will have 17 study visits at the study clinic. The study team will also call participants once a month over the phone.

The 2 groups in the trial

  • Ritlecitinib higher doseTreatment being tested

    Participants will receive 1 ritlecitinib higher dose capsule once a day (QD) and 1 placebo lower dose capsule QD orally for up to 3 years. Participants who meet the protocol-defined treatment discontinuation criteria based on not achieving the required efficacy threshold will be switched to placebo but will remain in the study. Those participants will receive 1 placebo higher dose capsule QD and 1 placebo lower dose capsule QD.

  • Ritlecitinib lower doseTreatment being tested

    Participants will receive 1 ritlecitinib lower dose capsule once a day (QD) and 1 placebo higher dose capsule QD orally for up to 3 years. Participants who meet the protocol-defined treatment discontinuation criteria based on not achieving the required efficacy threshold will be switched to placebo but will remain in the study. Those participants will receive 1 placebo higher dose capsule QD and 1 placebo lower dose capsule QD.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031
Plain-language title
Long-term ritlecitinib study for children with severe alopecia areataGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07029828, who can take part
Record updated
15 October 2026